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ABSTRACT
PARP-1 interacts with and poly(ADP-ribosyl)ates
p53 and topoisomerase I, which both participate
in DNA recombination. Previously, we showed that
PARP-1 downregulates homology-directed double-
strand break (DSB) repair. We also discovered that,
despite the well-established role of p53 as a global
suppressor of error-prone recombination, p53
enhances homologous recombination (HR) at the
RARa breakpoint cluster region (bcr) comprising
topoisomerase I recognition sites. Using an SV40-
based assay and isogenic cell lines differing in
the p53 and PARP-1 status we demonstrate that
PARP-1 counteracts HR enhancement by p53,
although DNA replication was largely unaffected.
When the same DNA element was integrated in an
episomal recombination plasmid, both p53 and
PARP-1 exerted anti-recombinogenic rather than
stimulatory activities. Strikingly, with DNA substra-
tes integrated into cellular chromosomes, enhance-
ment of HR by p53 and antagonistic PARP-1 action
was seen, very similar to the HR of viral minichromo-
somes. siRNA-mediated knockdown revealed the
essential role of topoisomerase I in this regulatory
mechanism. However, after I-SceI-meganuclease-
mediated cleavage of the chromosomally integra-
ted substrate, no topoisomerase I-dependent effects
by p53 and PARP-1 were observed. Our data
further indicate that PARP-1, probably through
topoisomerase I interactions rather than poly(ADP-
ribosyl)ation, prevents p53 from stimulating spon-
taneous HR on chromosomes via topoisomerase I
activity.
INTRODUCTION
PARP-1 plays fundamental roles in the recruitment and
modulation of enzymatic and regulatory factors involved
in transcription, DNA replication, repair and recombina-
tion [reviewed in (1–3)]. Importantly, PARP-1 catalyses
poly(ADP-ribosyl)ation of many of these proteins including
itself and dissociates from DNA after auto-modiﬁcation (4).
PARP-1 is enzymatically activated by binding to single-strand
breaks (SSBs) and participates in base excision repair (5,6).
Given that PARP-1 also recognizes double-strand breaks
(DSBs), interacts with Ku70/80, the catalytic subunit of
DNA-dependent protein kinase (DNA-PKcs), and the RecQ
helicase WRN, and regulates the biochemical activities of
DNA-PKcs and WRN (7–10), several groups investigated
potential activities of PARP-1 in DSB repair. Moreover,
two recent studies showed that dysfunction of homology-
directed DSB repair sensitizes cells to PARP inhibition sug-
gesting that PARP enzymatic activity is required to avoid the
accumulation of lesions which are repaired by homologous
recombination (HR) (11,12).
DSBs are caused spontaneously during physiological DNA
processing in replication, immunoglobulin gene diversiﬁca-
tion and meiosis and can arise from exogenous DNA-
damaging agents, including ionizing radiation or cancer
chemotherapeutic agents. The two major pathways of DSB
repair are nonhomologous end joining (NHEJ) and HR
(13,14). In the NHEJ pathway, Ku70 and Ku80 bind the
DSB, followed by recruitment and activation of DNA-PKcs,
which mediates synapsis and recruits XRCC4 and DNA
Ligase IV. In mammalian cells HR requires a protein complex
comprising Mre11, Rad50 and Nbs1 for DSB recognition and
end resection to yield 30-ssDNA tails. Subsequent strand
exchange between the processed ssDNA and an intact homo-
logous duplex are catalysed by Rad51. This reaction is facil-
itated by the DNA end-protecting protein Rad52, the DNA-
dependent ATPase and SNF2/SWI2 family member Rad54, as
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doi:10.1093/nar/gkj509well as by the Rad51 paralogs Rad51B, Rad51C, Rad51D,
Xrcc2 and Xrcc3. The breast cancer related gene product
BRCA2 is thought to assist Rad51 ﬁlament assembly on
ssDNA coated by replication protein A (RPA) (15). BLM
and WRN, mutated in Bloom’s and Werner’s syndrome,
respectively, unwind DNA, and WRN additionally exhibits
exonucleolytic activity. These enzymes may play a role in
resolving aberrantly paired structures, particularly during
error-prone Rad51-dependent recombination at stalled repli-
cation forks (16).
Waldman and Waldman (17) observed lower frequencies
of illegitimate recombination after treatment with an inhibitor
of poly(ADP-ribosyl)ation. Consistently, Rudat et al. (18)
found that overexpression of the mere DNA-binding domain
of PARP-1 (PARP-DBD), which causes trans-dominant
inhibition of poly(ADP-ribosyl)ation, inhibits rejoining of
ionizing radiation-induced DSBs, suggesting that PARP-1
counteracts NHEJ when stably bound to DNA strand inter-
ruptions. On the other hand, in a recent biochemical study,
Audebert et al. (19) discovered that PARP-1 provides synapsis
activity on a novel route for DSB rejoining that complements
the DNA-PK-dependent pathway. In agreement with the
latter idea, poly(ADP-ribose) colocalizes with the break
sensor Mre11, when nascent opened ends are generated
during the coding end resolution stage of V(D)J recombina-
tion, but only in DNA-PKcs-negative cells (20). High levels of
sister chromatid exchange (SCE) in cells from PARP-1
 / 
mice indicated a role for PARP-1 in protecting against
excess HR (21,22). Recently, Shibata et al. (23) also provided
in vivo evidence for a role of PARP-1 in suppressing deletion
and insertion mutations which accompany chromosomal
rearrangements in response to alkylation treatment. Consist-
ently, Schultz et al. (24) noticed a hyperrecombination
phenotype in cells from PARP-1
 /  mice as well as after
treatment of wild-type cells with an inhibitor of poly(ADP-
ribosyl)ation, as indicated by increased nuclear Rad51 foci
formation. However, no signiﬁcant rate change was seen in
homology-directed repair of a single DSB after chemical
PARP-1 inhibition, although similar treatments caused stimu-
lation of intrachromosomal (25) and extrachromosomal (26)
HR as well as homology-directed gene targeting (27). In our
previous work, we used a rapid, ﬂuorescence-based recom-
bination assay in order to better discriminate between early
DSB repair and subsequent apoptotic processes, which indir-
ectly may enhance DSB repair (28). The results demonstrated
a reduction of homology-directed DSB repair frequencies
by exogenously expressed PARP-1. On the other hand,
using a similar assay, Yang et al. (29) did not ﬁnd evidence
for interference of PARP-1 with DSB repair, although
enhancement of Rad51 foci formation and SCE in cells
from PARP-1
 /  mice was conﬁrmed. Additionally, delayed
S-phase progression of PARP-1
 /  cells was detected after
replication arrest, suggesting a role in the recombinative
reactivation of stalled replication forks.
The p53 tumor suppressor protein represents another
PARP-1 target and has been established as an antagonist of
error-prone HR events (30–35). Accumulating evidence has
further demonstrated that p53 regulates HR independently
of its transcriptional transactivation, cell cycle control and
pro-apoptotic functions. Rather, p53 is likely to interfere
with HR through physical interactions with Rad51, Rad54,
RPA, BRCA1, BRCA2, BLM and/or WRN, and the DNA
intermediates of homologous exchange. Similarly, p53 was
also found to inhibit error-prone NHEJ (36–38). Suprisingly,
when applying a speciﬁcally designed SV40-based recom-
bination test, we discovered that p53 upregulates recombina-
tion within a fragment of the RARa breakpoint cluster region
(bcr), which comprises two perfect topoisomerase I recogni-
tion sequences and is responsive to the topoisomerase I inhi-
bitor camptothecin (39). A functional link between p53 and
topoisomerase I had already been suggested by the fact
that p53 forms stable complexes with topoisomerase I and
enhances topoisomerase I-mediated relaxation of supercoiled
DNA (40,41). Mutant analyses showed that members of the
Rad52 epistasis group are involved in the repair of topoi-
somerase I–DNA complexes, thus indicating a critical role
of the homology-directed pathway (42,43).
Based on the ﬁndings that PARP-1 interacts with and
poly(ADP-ribosyl)ates p53 and topoisomerase I, which both
have been implicated in HR (30–32,39,44–49), we examined
the effect of PARP-1 on p53- and topoisomerase I-dependent
recombination. For this purpose we adapted and applied our
cellular assay systems for analyses of recombination within
extrachromosomal plasmid DNA substrates, SV40 minichro-
mosomes and cellular chromosomes (35,39,50). To distin-
guish possible inﬂuences of direct physical interactions
from those due to enzymatic activities of PARP-1, we addi-
tionally analysed the C-terminally truncated PARP-1 mutant
PARP-DBD. We demonstrate that p53 stimulates recombi-
nation through topoisomerase I, whereas PARP-1 abrogates
this effect, and we deﬁne the conditions required for these
processes.
MATERIALS AND METHODS
Plasmid constructs and topoisomerase I knockdown
The plasmids for extrachromosomal HR measurements were
constructed by Sal I insertion of the 0.3 kb RARa bcr frag-
ment (39) in both orientations in place of the hygromycin
resistance cassette in the pHR-EGFP/30EGFP plasmid (36).
Thus, two plasmids, pHR-EGFP/30EGFP-Rarafwd and pHR-
EGFP/30EGFP-Rararev were constructed, with the Rara bcr
fragment being localized between two disrupted EGFP genes.
Plasmids pPARP31, pPARP6 (51,52) and pCMV-p53
(BD Biosciences Clontech, Heidelberg) direct overexpres-
sion of full-length PARP-1, the DNA-binding domain of
PARP-1, and p53, respectively, have been described pre-
viously. DNA-modifying enzymes were purchased from
New England Biolabs, Frankfurt/Main.
To generate SV40 genomes carrying a 398 bp fragment
from the 30-untranslated region (30-UTR) of the PARP gene
without topoisomerase sequences (53), we transferred the
HindIII fragment after blunt end formation from the PARP
30-UTR into the SmaI site within the Cla linker of shortened
SV40 genome derivatives (39). The resulting vector set with
a pUC-SV40-Cla, a pUC-SV40-tsVP1(196Y)-Cla and a
pUC-SV40-tsVP1(290T)-Cla derivative carried the foreign
sequence in the same orientation. Foreign sequences and
insertion sites were veriﬁed by use of the ABi PRISM Big
Dye Ready Reaction Cycle Sequencing kit and an ABi 377
sequencer.
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the synthesis of siRNAs targeting topoisomerase I mRNA
(54) the following oligonucleotides were synthesized (Ther-
mohybaid, Ulm): AR-TopoI10-fwd, 50-GATCCCCAGCAG-
AGGAAGTAGCTACGTTCAAGAGACGTAGCTACTTCC-
TCTGCTTTTTTGGAAA-30; AR-TopoI10-rev, 50-AGCTTT-
TCCAAAAAAGCAGAGGAAGTAGCTACGTCTCTTGAA-
CGTAGCTACTTCCTCTGCTGGG-30. After annealing and
50-terminal phosphorylation the oligonucleotides were ligated
into the BglII/HindIII digested pSUPER plasmid. In parallel,
the following two sets of oligonucleotides were synthesized,
cloned and tested under the conditions described above:
AR-TopoI9-fwd, 50-GATCCCCCAGTTGATGAAGCTGG-
AAGTTCAAGAGACTTCCAGCTTCATCAACTGTTTTTG-
GAAA-30; AR-TopoI9-rev, 50-AGCTTTTCCAAAAACAG-
TTGATGAAGCTGGAAGTCTCTTGAACTTCCAGCTTC-
ATCAACTGGGG-30 and AR-TopoI11-fwd, 50-GATCCCC-
GCAGCCCGAGGATGATCTTTTCAAGAGAAAGATCAT-
CCTCGGGCTGCTTTTTGGAAA-30; AR-TopoI11-rev, 50-
AGCTTTTCCAAAAAGCAGCCCGAGGATGATCTTTCT-
CTTGAAAAGATCATCCTCGGGCTGCGGG-30. Whereas
pSUPER plasmid containing AR-TopoI11-fwd/AR-TopoI11-
rev showed no knockdown activity, both plasmids with
AR-TopoI9-fwd/AR-TopoI9-rev and AR-TopoI10-fwd/AR-
TopoI10-rev were positive. pSUPER-TopoI with AR-
TopoI10-fwd/AR-TopoI10-rev was the most effective and
was, therefore, employed in further experiments. To verify
RNA interference under recombination assay conditions
(see below), we electroporated KMV(HR-EGFP/30EGFP)
cells (36) with 15 mg pSUPER-TopoI (AR-TopoI10-fwd/
AR-TopoI10-rev) DNA plus empty vector, p53 expression
plasmid and/or PARP-1 expression plasmid. Subsequently,
cells were returned to growth conditions for 48–72 h and
topoisomerase I protein expression was analysed by western
blotting. In these different cell types, topoisomerase I was
downregulated to 40–50% of the protein expression levels
in control cells correspondingly transfected with pSUPER
plus empty vector, p53 expression plasmid, and/or PARP-1
expression plasmid (mean values from two to four western
blots as calculated from topoisomerase I-speciﬁc band intens-
ities after normalizing with actin or tubulin-speciﬁc band
intensities).
Mammalian cell culture, cell cycle profiles and viral
DNA synthesis
For SV40-based recombination assays LMV, LMV-PARP,
LMV-p53her and LMV-p53her/PARP cell lines, described
in Su ¨sse et al. (28), were used. Brieﬂy, LMV is derived
from the parental line LLC-MK2 from rhesus monkey
(Macaca mulatta) kidney, stably expressing the estradiol-
inducible transcriptional transactivation factor Gal4ERVP.
LMV-PARP cells additionally express PARP-1 via the
Gal4ERVP-responsive plasmid pGC-PARP-1, LMV-p53her
cells express the estradiol-responsive wild-type p53 fusion
protein p53her, and LMV-p53her/PARP cells express both
PARP-1 and p53her. These cell lines were cultivated at
37 C in DMEM supplemented with 10% foetal calf serum
(FCS) (PAA Laboratories, Pasching). Estradiol-like sub-
stances were removed from FCS and used in combination
with phenol-red free medium for the propagation of cell
cultures before analysis (28). During recombination measure-
mentscultures were incubated in the presence of 1mM b-estra-
diol (Sigma, Mu ¨nchen). CV1 and COS1 cells were propagated
for the production of virus particles and for the determination
of plaque forming units (PFUs) as described previously (50).
For ﬂuorescence-based recombination experiments we
utilized KMV cells, which had been subcloned from the leuk-
emia cell line K562 for stable Gal4ERVP expression (36).
Additionally, we applied KMV cells with chromosomally
integrated pHR-EGFP/30EGFP recombination plasmid,
named KMV(HR-EGFP/30EGFP) (36). For maintenance, the
growth medium RPMI  12/1 supplemented with 10% FCS
and 2% L-Glutamine (Biochrom AG, Berlin) was used. The
cell cultures used in this work were free from mycoplasma
contamination.
KMV(HR-EGFP/30EGFP) cells were analysed for cell
cycle progression and for apoptosis 72 h after transfection
and cultivation under the conditions of the recombination
assay. According to our published protocol (55), we harvested
cells by centrifugation which was followed by ﬁxation, prop-
idium iodide staining and FACS  analysis.
To measure de novo SV40-DNA synthesis, we labelled
cells on 60 mm dishes with 30 mCi of [
3H]thymidine for
1 h at the indicated times after infection, puriﬁed viral gen-
omes, quantiﬁed [
3H]thymidine incorporation and calculated
rates of viral DNA synthesis as described previously (39).
Recombination assays
SV40-based recombination experiments, including plaque
assays for the quantitative determination of reconstituted
viral particles, were performed and evaluated exactly as
detailed in Boehden et al. (39). To obtain recombination
frequencies, the ratios between the values from double infec-
tions with tsVP1-SV40 mutants and from control infections
with the same infectious units of wtVP1-SV40 were determ-
ined for each single assay condition. This procedure served
to normalize recombination frequencies, in order to exclude
rate deviations caused by growth regulatory effects with
the individual cell line used, differences in cell lethality,
and alterations in virus propagation related to the speciﬁc
DNA element inserted and/or alterations of transcriptional
and translational activities. During recombination assays,
the two tsVP1-SV40 mutants and the control wtVP1-SV40
virus carried the same foreign sequence of interest.
To quantify EGFP reconstitution as a measure of chromo-
somal recombination frequencies KMV(HR-EGFP/30EGFP),
cells were electroporated at 200 V and 1050 mF with a
total amount of 40 mg plasmid DNA. For p53, PARP-1 and
PARP-DBD expression 5 mg of plasmid DNA were included
each and replaced by the corresponding empty vectors in
controls. For experiments involving pSUPER-TopoI we
used 15 mg of the plasmid mediating RNA interference. For
experiments with targeted cleavage of the chromosomally
integrated HR-EGFP/30EGFP recombination substrate, 5 mg
of pCMV-I-SceI were also included. After electroporation
cells were cultivated for 72 h at 37 C. Subsequently, cells
were analysed by ﬂow cytometry by use of a FACS Calibur
Calibur FACScan (Becton & Dickinson, Heidelberg) using the
488 nm laser line for excitation in combination with the ﬁlters
used for green (Fl1) and orange (Fl2) ﬂuorescence detection.
1038 Nucleic Acids Research, 2006, Vol. 34, No. 3One hundred thousand living cells were analysed each to
distinguish between EGFP-positive and -negative cells by
the diagonal gating method in the Fl1/Fl2 dot plot (36,56).
To determine the individual expression levels of EGFP in the
presence or absence of p53, PARP-1, PARP-DBD and/or
topoisomerase I, each experiment included a cotransfection
with a control plasmid, which carried wild-type EGFP at
the acceptor position. The fraction of EGFP-positive cells
was individually determined and was used to normalize
each single recombination frequency, to exclude rate
deviations related to growth regulatory effects, differences
in growth, cell lethality, transcriptional and translational
(a)
(b) (c) (d)
Nucleic Acids Research, 2006, Vol. 34, No. 3 1039activities (36). The statistical signiﬁcance of differences was
determined using Student’s t test for unpaired samples.
To assess recombination with extrachromosomal substrate
DNA,KMVcellswere transfected with Lipofectamine  2000
Reagent (Invitrogen, Karlsruhe) and 4 mg of total plasmid
DNA. The recombination plasmids pHR-EGFP/30EGFP-
Rarafwd and pHR-EGFP/30EGFP-Rararev were applied at
0.5 mg each. For p53, PARP-1 and PARP-DBD expression,
0.5 mg of plasmid DNA were included each and substituted
by the corresponding empty vectors in controls. After cultiva-
tion for 48 h at 37 C expression of the reactivated EGFP
was measured via FACS  cytometry as described above.
Western blot analysis
Immunoblot analysis was done essentially as described in
Akyu ¨z et al. (36). Brieﬂy, total cell extracts were prepared
from KMV or KMV(HR-EGFP/30EGFP) cells 48 h after
transfection under recombination assay conditions. Proteins
were separated on 8% polyacrylamide–SDS gels and trans-
ferred to Immobilon-P Transfer Membranes (Millipore,
Schwalbach). The presence of topoisomerase I was revealed
by the human antiserum Scl-70 (1:5000; Topogen, Port
Orange) followed by incubation with peroxidase-conjugated
secondary antibody (Biomol Rockland, Vienna, Austria).
For western blot analyses of PARP-1 and PARP-DBD we
used goat polyclonal IgG N-20 (1:10000; Santa Cruz, Heidel-
berg), for human p53 we applied the monoclonal antibody
DO1 (1:10000; Calbiochem, Bad Soden) and anti-mouse
and anti-goat IgG peroxidase-conjugated secondary antibod-
ies, respectively (Biomol Rockland, Vienna; Dianova/Jackson
Immuno, Hamburg). To verify equal loading, tubulin or actin
were detected by goat serum I-19 (1:1000; Santa Cruz,
Heidelberg) and the mAb DM1A (1:1000; abcam,Cambridge,
MA), respectively. Western blot signals were visualized
by enhanced chemiluminescence (SuperSignal West Dura;
Pierce/Perbio Science, Bonn).
RESULTS
Effect of PARP-1 on the p53-dependent regulation of
recombination between SV40 minichromosomes
Although p53 has been established as a surveillance factor
that downregulates HR in a DNA sequence-independent
manner, we observed recently a stimulatory effect of p53
on recombination within a 0.3 kb DNA fragment from the
RARa bcr (33–35,39). There has been controversy about
the functional links of PARP-1 to p53 (31,57–63) and about
the possible role of PARP-1 in homology-directed DNA
repair (24,28,29). We therefore applied our previously
described SV40-based assay (39,50) in order to examine
recombination under conditions where p53 exerts a positive
or a negative regulatory effect. The SV40-based assay relies
on the genetic exchange between SV40 genomes with
different VP1-mutations causing temperature sensitivity
(Figure 1a). Virus particles were produced at the permissive
temperature (32 C) and DNA recombination was tested
after double infection of target cells at the non-permissive
temperature (39 C). Genetic reconstitution of wild-type
VP1 (wtVP1) virus genomes was monitored by plaque
assays at 39 C using supernatants from the doubly infected
cultures. Plaque formation after wtVP1-SV40 infection was
scored in parallel in order to normalize PFUs from coinfec-
tion experiments. For the analysis of RARa bcr-dependent
recombination we generated virus particles from shortened
SV40 genome variants [SV40-tsVP1(290T)-Cla, SV40-
tsVP1(196Y)-Cla, SV40-wtVP1-Cla] with the 0.3 kb RARa
bcr sequence cloned into a synthetic ClaI restriction site
adjacent to the mutations causing temperature sensitivity
(Figure 1a).
To address whether PARP-1 plays a role during recombi-
nation between SV40 minichromosomes, we made use of a
representative set of primate cell lines conditionally express-
ing exogenous PARP-1 in a wild-type p53-positive or
-negative background, respectively (28). The parental line
LMV represents an LLC-MK2 derivative expressing the
estradiol-inducible transcription factor Gal4ERVP, which dir-
ects expression of PARP-1 from pGC-PARP-1 plasmid. LMV
subclones with stably integrated pGC-PARP-1 expression
plasmid (LMV-PARP), with pSV53her plasmid for con-
stitutive expression of the estradiol-responsive fusion protein
containing wild-type p53 and the estradiol-binding domain
of the human estrogen receptor (LMV-p53her), and with
both plasmids (LMV-p53her/PARP) have been characterized
previously with respect to protein expression levels, transcrip-
tional, cell cycle regulatory and pro-apoptotic responses (28).
Consistent with our earlier ﬁndings (39), expression of wild-
type p53 in LMV-p53her as compared with LMV cells
caused a 3.8-fold stimulation (P ¼ 0.034) of recombina-
tion between SV40 genomes carrying the RARa bcr frag-
ment (Figure 1b). Similar recombination frequencies were
measured for LMV and LMV-PARP cells, i.e. no major inﬂu-
ence of PARP-1 on RARa bcr-dependent recombination was
Figure 1. Influence of PARP-1 on recombination in the SV40-based assay. (a) Principle of the recombination test. Temperature sensitive SV40 mutants [SV40-
tsVP1(290T)-Cla,SV40-tsVP1(196Y)-Cla]usedforrecombinationmeasurements(50)carrytheRARabcrfragmentwithintheClaIsiteofasyntheticClaIlinker(39).
Perfect topoisomerase I recognition sequences and t(15;17) translocation sites found within the RARa bcr fragment in acute promyelocytic leukemia patients are
marked.ThegenomiclocalizationofthefragmentwithintheRARabcrisindicated(squares,exons,blacklines,introns,codingregions,grey,UTRs,striped).Virus
particles were amplifiedat the permissivetemperatureof 32 C and used for doublyinfectingcells with the RARa bcr variantsof SV40-tsVP1(290T)-Cla and SV40-
tsVP1(196Y)-Cla at 39 C. SV40-wtVP1-Cla virus reconstitution by recombination was scored by reinfection and plaque assays at 39 C. Control infections with the
SV40-wtVP1-Cla variantserved to calculate recombination frequencies [(PFUscoinfection/(PFUs SV40-wtVP1-Cla infection · fraction of doublyinfectedcells)].
Mean recombination frequencies and SD from two to four independent quadruplicate measurements are shown graphically. (b) Recombination at the RARa bcr
fragment.RecombinationassayswereperformedbydoublyinfectingLMV( wtp53, PARP-1),LMV-p53her(+wtp53, PARP-1),LMV-PARP( wtp53,+PARP-
1) and LMV-p53her/PARP (+wtp53, +PARP-1) cells (28) using SV40-tsVP1(290T)-Cla, SV40-tsVP1(196Y)-Cla, and SV40-wtVP1-Cla derivatives comprising the
RARabcrfragment.(c)RecombinationbetweenSV40genomeswithoutforeignsequence.BasalrecombinationfrequenciesinLMV,LMV-p53her,LMV-PARPand
LMV-p53her/PARPcellsweredeterminedbyuseofthecontrolSV40variantsSV40-tsVP1(290T),SV40-tsVP1(196Y)andSV40-wtVP1.(D)Recombinationbetween
SV40genomesatthe30-UTRofthePARPgene.RecombinationassayswereperformedbydoublyinfectingLMV,LMV-p53her,LMV-PARPandLMV-p53her/PARP
cellsusingSV40-tsVP1(290T)-Cla,SV40-tsVP1(196Y)-ClaandSV40-wtVP1-CladerivativescomprisingafragmentfromthePARP30-UTRwithouttopoisomeraseI
sites (53).
1040 Nucleic Acids Research, 2006, Vol. 34, No. 3detected. Most interestingly, however, we did not see recom-
bination enhancement in LMV-p53her/PARP cells suggest-
ing that PARP-1 counteracts p53-mediated stimulation of
recombination between SV40 minichromosomes carrying
the RARa bcr subregion. In sharp contrast to the results
obtained with RARa bcr SV40 variants, recombination
between SV40 genomes without foreign sequence was
repressed by wild-type p53 in LMV-p53her cells (3.5-fold,
P ¼ 0.008) (Figure 1c). LMV-PARP cells showed a 1.8-
fold reduced recombination frequency. A downregulatory
effect of PARP-1 was not detected in LMV-p53her/PARP
cells, possibly due to the formation of DSBs by apoptotic
processes which overcome anti-recombinogenic activities
of p53 and PARP-1 (28). Possibly, this effect is seen only
at speciﬁc response sequences or at low basal recombination
frequencies, i.e. below 5 · 10
 4. Figure 1d shows additional
control data involving a genomic sequence, which is simi-
larly sized as the RARa bcr fragment (0.4 kb) and displays
recombination-promoting features (recombination frequency
for LMV: 67 · 10
 4), but lacks strong topoisomerase I
recognition sites. The results depicted in this ﬁgure
conﬁrm that wild-type p53 in LMV-p53her represses rather
than stimulates recombination, when topoisomerase I sites
are missing in the foreign DNA element (3.1-fold,
P ¼ 0.025). PARP-1 expression in LMV-PARP cells caused
a 3.5-fold downregulation. Expression of both p53 and
PARP-1 in LMV-p53her/PARP cells repressed recombi-
nation 3.7 fold.
Effect of PARP-1 and p53 on viral DNA synthesis
Since replication arrest had been shown previously to stimu-
late recombination between SV40 minichromosomes (64,65),
the impact of p53 and PARP-1 on RARa bcr-dependent
DNA synthesis was examined. We measured [
3H]thymidime
incorporation into viral DNA at various times after infection
(Figure 2). As reported previously (39), de novo DNA syn-
thesis was slightly reduced by wild-type p53 (LMV-p53her),
both for SV40 genomes without foreign sequence (control)
and for RARa bcr comprising derivatives. Compared with
LMV, expression of PARP-1 in LMV-PARP and LMV-
p53her/PARP cells did not cause any major changes in
the [
3H]thymidime incorporation pattern compared with
the control SV40 and the RARa bcr-variant. However,
we cannot fully exclude a minor inﬂuence of replication
on the recombination activities determined. Nevertheless,
effects on recombination frequencies by PARP-1 expression
in a wild-type p53-positive or -negative background
failed to show a close correlation with changes in DNA
replication rate.
Figure 2. DNAsynthesis.SV40DNAreplicationwasdeterminedinLMV(closeddiamonds),LMV-p53her(greysquares),LMV-PARP(closedtriangles)andLMV-
p53her/PARP (grey crosses) cells after infection with control SV40 and with the derivative comprising the RARa bcr fragment, respectively. [
3H]thymidine
incorporationwasdeterminedatvarioustimespostinfection(hpi).TocalculaterelativeDNAsynthesisratesthemaximumrateforSV40withoutforeignsequencein
LMV cells 24 hpi was defined as 100%.
Nucleic Acids Research, 2006, Vol. 34, No. 3 1041p53 and PARP-1 downregulate recombination in
extrachromosomal plasmid substrates
To further delineate the inﬂuence of p53 and PARP-1 in
HR at the RARa bcr subregion, we investigated possible
SV40-speciﬁc effects. For this purpose, we constructed
plasmids pHR-EGFP/30EGFP-RARafwd and pHR-EGFP/
30EGFP-RARarev, which allow assessment of HR between
mutated EGFP genes (HR-EGFP and 30EGFP) in the vicinity
(a)
(b) (c)
1042 Nucleic Acids Research, 2006, Vol. 34, No. 3of the RARa bcr fragment (Figure 3a). This enabled us to use
the ﬂuorescence-based assay (36) which had successfully been
used to study p53 and PARP-1 in DSB repair (28). To quantify
recombination frequencies in this transient transfection
assay, EGFP reconstitution is monitored, i.e. the ratios
between green ﬂuorescent cells and the total number of
cells in the population are determined by ﬂow cytometry.
In order to relate cellular recombination events to the fraction
of successfully transfected cells, we performed cotransfec-
tions with wild-type EGFP control plasmid parallel to each
recombination experiment. We also wanted to exclude pos-
sible indirect effects related to DNA structure and, therefore,
inserted the RARa bcr fragment between HR-EGFP and
30EGFP in both orientations (Figure 3a).
To study homology-directed repair as a function of p53
activity, we lipofected KMV cells with the recombination
plasmids pHR-EGFP/30EGFP-RARafwd or pHR-EGFP/
30EGFP-RARarev and pBS control plasmid or pCMV-p53.
pCMV-p53 directs expression of wild-type p53 in KMV cells,
which are derived from the parental line K562 with homo-
zygously deleted p53 (36). Surprisingly, KMV cells ectopic-
ally expressing p53 (Figure 3c) showed a reduction in
recombination frequency by 54% rather than an increase
(Figure 3b). Having shown that PARP-1 counteracts p53-
dependent recombination increases at the RARa bcr in the
SV40-based assay, we investigated the role of PARP-1 with
the episomal substrates pHR-EGFP/30EGFP-RARafwd and
pHR-EGFP/30EGFP-RARarev. To separate the enzymatic
PARP-1 function from its DNA-binding activity we also
tested the effect of overexpression of the mere DNA-
binding domain of PARP-1 (PARP-DBD), which is devoid
of enzymatic activity and causes trans-dominant inhibition
of poly(ADP-ribosyl)ation (51,52). For this purpose, KMV
cells were not only transfected with one of the recombina-
tion plasmids together with or without pCMV-p53 but also
with plasmids pPARP31 or pPARP6 which direct expres-
sion of PARP-1 and PARP-DBD in KMV cells, respectively
(Figure 3c) (28). For PARP-1 and PARP-DBD expression
in the absence of p53, we observed a reduction by 21%
(P ¼ 0.000) and 16% (P ¼ 0.030), respectively, with pHR-
EGFP/30EGFP-RARafwd as a recombination substrate,
which was similar to the reduction of 27% (P ¼ 0.000)
and 26% (P ¼ 0.000) with pHR-EGFP/30EGFP-RARarev
(Figure 3b). In the presence of p53, expression of PARP-1
or PARP-DBD did not induce any additional, signiﬁ-
cant changes in recombination frequency at the given
protein/DNA substrate ratios (28). Equivalent results were
obtained with a similarly sized 0.4 kb fragment from the
late region of the SV40 genome containing one topoisomerase
I recognition sequence and a 1.3 kb hygromycin resistance
cassette with multiple topoisomerase I recognition sequences
(see below), thereby excluding a major regulatory inﬂuence
from the speciﬁc DNA sequence (data not shown). Taken
together, both p53 and PARP-1 as well as the PARP-DBD
diminished HR activities with plasmid substrates independ-
ently of DNA sequence content, length and orientation
between the substrates for homologous exchange.
p53 stimulates HR on cellular chromosomes via
topoisomerase I and PARP-1 counteracts this
stimulatory effect
So far, stimulation of recombination by p53 has only been
observed with SV40 minichromosomes (39). To clarify
whether chromosomal features are critical for this effect,
we applied the well-characterized, p53-deﬁcient KMV cell
line with a stably integrated HR-EGFP/30EGFP recombina-
tion substrate (36). Within HR-EGFP/30EGFP, mutated EGFP
genes are ﬂanking a spacer region consisting of a hygromycin
resistance cassette with altogether eight perfect topoisome-
rase I recognition sequences (Figure 4a). KMV(HR-EGFP/
30EGFP) cells were electroporated with pBS or pCMV-p53
and concomitantly with pSUPER control plasmid or pSUPER-
TopoI, which directs the synthesis of siRNAs targeting
topoisomerase I mRNA, thereby causing a decrease in topoi-
somerase I protein level (Figure 4c). Topoisomerase I was
silenced previously in HCT116 cells, when using a vector
stably expressing siRNA hairpins called pREP4/Top1 (66).
p53 expression resulted in a 2.9-fold increase of spontaneous
HR (P ¼ 0.011; Figure 4b). Downregulation of endogenous
topoisomerase I in cells without p53 led to a 51% reduction
of the recombination frequency (not signiﬁcant; P ¼ 0.087).
Strikingly, knocking down topoisomerase I expression fully
suppressed the recombination increase caused by p53 expres-
sion (5.1-fold, P ¼ 0.002). Next, KMV(HR-EGFP/30EGFP)
cells were additionally transfected with the PARP-1 and
PARP-DBD expression plasmids pPARP31 and pPARP6,
respectively. In the absence of p53, neither PARP-1 nor
PARP-DBD altered recombination frequencies signiﬁ-
canly. Reminiscent of the inﬂuence of PARP-1 on HR
between RARa bcr fragment carrying SV40 genomes, we
did not detect any signiﬁcant p53-mediated recombination
Figure 3. Influenceofp53,PARP-1andPARP-DBDexpressiononrecombinationwithplasmidepisomes.(a)Designoftherecombinationplasmidscomprisingthe
RARabcrsequence.TheEGFP-basedrecombinationplasmidHR-EGFP/30EGFP(36)wasmodifiedsuchthattheRARabcrfragment(39)waspositionedasspacer
between the following DNA elements serving as substrates for homology-directed repair: HR-EGFP, an internally mutated EGFP gene under the control of the
CMV promoter, following a puromycin resistance cassette, and the N-terminally truncated 30EGFP gene. Within the spacer region the RARa bcr fragment was
inserted in the forward and the reverse orientation to construct plasmids pHR-EGFP/30EGFP-RARafwd and pHR-EGFP/30EGFP-RARarev, respectively.
(b) Recombination after p53, PARP-1 or PARP-DBD expression. KMV cells (36) were subjected to lipofection with the plasmids pBS or pCMV-p53 together
with pBS, pPARP31 or pPARP6, for expression of wild-type p53 (wtp53), full-length PARP-1 and PARP-DBD, respectively. For determination of recombina-
tionfrequencieseitherplasmidpHR-EGFP/30EGFP-RARafwd(RARabcrforward)orpHR-EGFP/30EGFP-RARarevwascotransfected(RARabcrreverse).After
lipofection cells were cultivated for 48 h. Reconstitution of EGFP was monitored by FACS  analysis and recombination frequencies determined as the fraction
of green fluorescent cells within the population of non-fluorescent cells. Individual transfection efficiencies served to normalize each single recombination
frequency. Relative recombination frequencies were calculated by taking frequencies in control cells with pHR-EGFP/30EGFP-RARafwd or pHR-EGFP/
30EGFP-RARarev as 100% (absolute values: 4.3 · 10
 2 for forward, 4.2 · 10
 2 for reverse). Mean values and SEM from six to nine recombination measure-
mentsareshown.(c)Proteinexpression.p53-negativeKMVcellswerelipofectedwithpHR-EGFP/30EGFP-RARarevtogetherwithpBS(control)andpCMV-p53or
with pBS (control), pPARP6, and pPARP31 and total cell extracts prepared after 48 h of continued cultivation. Immunoblotting with the antibody DO1 and
goatpolyclonalN-20serumwasperformedto visualizeexpressionofwild-typep53 (wtp53),andPARP-1andPARP-DBD, respectively. Theasteriskmarksa band
that is detected by N-20 serum independently of the inclusion of expression plasmid.
Nucleic Acids Research, 2006, Vol. 34, No. 3 1043enhancement on the chromosomally integrated HR-EGFP/
30EGFP substrate after cotransfection with pPARP31 or
pPARP6. Similar observations were also made in cotransfec-
tion experiments with pSUPER-TopoI. Importantly, FACS 
analysis of PI stained cells demonstrated that neither topoi-
somerase I knockdown nor p53, PARP-1 or PARP-DBD
expression had a major inﬂuence on cell cycle distribution
or apoptosis induction under the conditions of the assay
(Figure 4d). Altogether these data indicated that diminished
topoisomerase I expression as well as increased PARP-1 and
PARP-DBD levels counteract spontaneous recombination on
cellular chromosomes in the presence of p53.
(a)
(b)
(d)
(c)
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after targeted cleavage of chromosomal substrate DNA
Having established a p53-topoisomerase I pathway in the
regulation of spontaneous recombination events, we were
interested in the functional links between p53 and topoi-
somerase I with respect to homology-directed DNA repair
if DSBs were artiﬁcially introduced by meganuclease
I-Sce I. For this purpose we performed recombination
measurements with KMV(HR-EGFP/30EGFP) cells as
shown in Figure 4 and additionally co-electroporated the
meganuclease I-Sce I expression plasmid pCMV-I-SceI.
HR-EGFP/30EGFP was designed such that an I-Sce I recog-
nition sequence is positioned within HR-EGFP allowing tar-
geted cleavage of this stably integrated recombination marker
gene (Figure 5a) (36). I-Sce I expression caused a 20-fold
overall increase of recombination frequencies (Figures 4b
and 5b). p53 expression resulted in a 88% decrease of recom-
bination (Figure 5b). In cells without p53, PARP-1 or PARP-
DBD expression caused reduction of frequencies by 32 and
21%, respectively. No additional PARP-1-dependent changes
were observed in cells electroporated with pCMV-p53. A sim-
ilar picture emerged in pSUPER-TopoI cotransfection experi-
ments. From these results we conclude that topoisomerase I
has no major inﬂuence on homology-directed repair once a
DSB has been introduced into the target, both in the presence
and absence of wild-type p53 or PARP-1.
DISCUSSION
We and others (24,28,29) showed previously that PARP-1 has
a negative regulatory role in HR, but it remained unclear
whether PARP-1 is involved in homology-directed repair
of DSBs, reactivation of stalled replication forks and/or
alternative HR pathways. In this work, we showed that
PARP-1 expression reduces homology-directed repair of a
targeted DSB on chromosomes as well as HR on different
extrachromosomal plasmid substrates, i.e. in a manner inde-
pendent of DNA replication and of speciﬁc DNA sequences.
PARP-DBD was similarly effective, strongly indicating
that the underlying mechanism is binding of the DNA sub-
strate via the ends or secondary structures (67). Supporting
this concept, Rudat et al. (18) found that overexpres-
sion of PARP-DBD inhibits rejoining of DSBs. p53 and
topoisomerase I both represent PARP-1-binding partners
and poly(ADP-ribosyl)ation substrates and play a role in
recombination (30–32,35,39,44,45,49). Therefore, we invest-
igated more closely possible links between PARP-1, p53 and
topoisomerase I in spontaneous and DSB-triggered HR. Func-
tional interactions between PARP-1 and wild-type p53 may
well have been overlooked in previous studies using mutant
p53 hamster cells, embryonic stem cells, in which p53 is
inactivated due to its cytoplasmic localization or embryonic
ﬁbroblasts with p53 gene mutations frequently occurring dur-
ing early passages (24,29).
Our results from RNA interference experiments ﬁrstly
demonstrate that p53 can stimulate HR in a manner strictly
depending on topoisomerase I, which is consistent with our
previous report revealing a similar degree of recombination
enhancement by either p53 expression or camptothecin treat-
ment (39). This stimulatory effect was detectable only if the
DNA recombination substrate, which carried topoisomerase I
recognition sequences in the neighborhood of the exchange
site, was localized on viral or cellular chromosomes. This
ﬁnding could mean that the cooperation between p53 and
topoisomeraseIdependsonchromatinstructure.Inthisregard,
it is interesting to note that Rubbi and Milner (68) discovered
a role of p53 in regulating chromatin remodelling which
may give access to the sites of topoisomerase I action.
Topoisomerase I preferentially interacts with supercoiled
DNA, which alternatively may be the basis for recruiting
the enzyme to DNA in the context of chromatin (69). Recom-
bination enhancement by p53 was no longer seen, when DSBs
were introduced within the DNA substrate. Instead, a net
decrease of HR was monitored after wild-type p53 expression.
Similarly, in the presence of naked plasmid DNA, the role
of wild-type p53 in controlling the ﬁdelity of HR dominated
over its topoisomerase I-dependent HR upregulation (35,70).
These observations strongly suggested that p53 and topoi-
somerase I cooperate in a pathway increasing the recombino-
genicity of the DNA substrate which becomes irrelevant
upon availability of highly recombinogenic DNA.
The recombination stimulatory role of p53 might simply be
achieved through stimulation of the topoisomerase I relaxa-
tion activity to relieve torsional strain (40,41). Another pos-
sible explanation has come from biochemical observations
made by Grosse and co-workers (46–48). These authors
demonstrated that a topoisomerase I–DNA complex can be
Figure 4. Recombinationoncellularchromosomesafterexpressionofp53,PARP-1andPARP-DBD,andconcomitantknockdownofendogenoustopoisomeraseI.
(a)StructureoftheDNAsubstrateforhomology-directedrepairinthecontextofcellularchromosomes.SubstrateHR-EGFP/30EGFPwaschromosomallyintegrated
in the p53-negative parental KMV line to yield KMV(HR-EGFP/30EGFP) cells (36). HR-EGFP/30EGFP comprises a puromycin resistance cassette, the HR-EGFP
cassette,andthe30EGFPgene(Figure3).Thespacerregioncontainsahygromycinresistancecassette(SV40promoter,closedsquare;hygromycinresistancegene,
open square) with eight perfect topoisomerase I recognition sequences. (b) Recombination as a function of p53, PARP-1 and topoisomerase I. KMV(HR-EGFP/
30EGFP) cells were co-electroporated with pBS or pCMV-p53 (wtp53) together with pBS, pPARP31 (PARP-1) or pPARP6 (PARP-DBD) and concomitantly with
pSUPER or pSUPER-TopoI (topoisomerase I knockdown) as indicated. Coelectroporations were followed by further cultivation for 72 h. Mean recombination
frequencies and SEM were determined from 10 recombination measurements each. For the determination of relative recombination frequencies, frequencies
incontrolcellswithpBSweretakenas100%(3 · 10
 5).EGFPwastypicallyexpressedin39–57%ofthecellselectroporatedwiththe12differentplasmidmixtures.
(c) Downregulation of topoisomerase I expression. KMV(HR-EGFP/30EGFP) cells were electroporated with 40 mg of pBS (control) or 15 mgo fpSUPER-TopoI
mediating RNA interference plus 25 mg of pBS control plasmid and cultivated for 48 h under conditions of the recombination assay. Endogenous topoisomerase I
levels were visualizedvia immunodetection with the human antiserumScl-70. Topoisomerase I from total cellular homogenatesappeared as the full-length protein
of 100 kDa and as a truncated version. Equal loading was verified by reincubation of the western blot with anti-actin antibodies. (d) Cellular features after
topoisomerase I knockdown. Cell cycle distribution and apoptosis were analysed flow cytometrically for propidium iodide stained KMV(HR-EGFP/30EGFP) cells
72haftertransfectionandcultivationundertheconditionsoftherecombinationassay.Thepercentageofcells(cellularfraction)withsub-G1DNAcontent(firstbar),
in G1 (second bar), S (third bar) and G2 phase (fourth bar) are illustrated for cells co-electroporated with pBS or pCMV-p53 (wtp53) together with pBS, pPARP31
(PARP-1) or pPARP6 (PARP-DBD) and concomitantly with pSUPER or pSUPER-TopoI (topoisomerase I knockdown) each. Mean values and SD from two
measurements each were calculated.
Nucleic Acids Research, 2006, Vol. 34, No. 3 1045recognized by one additional topoisomerase I molecule to
form the so-called topoisomerase I double cleavage complex.
Release of one cleavage complex together with the oligonuc-
leotide encompassing the DNA lesion creates an ssDNA gap
that provides an entry site for a foreign, complementary
DNA strand. p53 has a signiﬁcant stimulatory effect on this
double cleavage reaction and on the resulting recombination-
mediated repair events.
When p53-mediated HR stimulation was seen on SV40
or cellular chromosomes, coexpression of PARP-1 antagon-
ized this topoisomerase I-dependent effect (summarized in
Table 1). SSBs, including those produced by topoisomerase
I–DNA complex stabilization, are known to become conver-
ted into DSBs at the replication fork (71). Thus, anti-
recombinogenic effects of PARP-1 could theoretically stem
from its activities in the repair of SSBs (72). However, it has
been well documented that p53 inhibits rather than stimula-
tes HR in response to DSB formation at the replication fork,
which is why SSB repair activities are unlikely to play a role
during the p53- and topoisomerase I-dependent HR enhance-
ment observed in this study (64,73). PARP-1 expression did
not have a major inﬂuence on the DNA replication pattern or
(a)
(b)
Figure5. MeganucleaseI-SceI-triggeredDSBrepaironcellularchromosomesasafunctionofp53,PARP-1andtopoisomeraseI.(a)StructureoftheDNAsubstrate
for meganuclease I-Sce I-triggered DSB repair. Chromosomally integrated HR-EGFP/30-EGFP substrate contains a recognition sequence (closed triangle) for the
rare-cuttingI-SceImeganucleasewithintheHR-EGFPgenetotriggerhomology-directedDSBrepairafterI-SceIexpressionandtargetedcleavage (36).(b)I-SceI-
triggered recombination frequencies. After electroporation with pBS or pCMV-p53(wtp53) and pBS, pPARP31 (PARP-1) or pPARP6 (PARP-DBD) together with
pSUPER or pSUPER-TopoI (topoisomerase I knockdown) KMV(HR-EGFP/30EGFP) cells were cultivated for 72 h. Additionally, for meganuclease-mediated
cleavage of chromosomally integrated HR-EGFP/30EGFP substrate pCMV-I-SceI was co-electroporated each. Mean values including SEM of relative recombina-
tion frequencies are given for 12 measurements each. Recombination frequencies in KMV(HR-EGFP/30EGFP) cells with pBS control plasmid were taken as 100%
(5.7 · 10
 4).
Table 1. Comparative analysis of recombination data for p53 and PARP-1
Recombination substrates
at topoisomerase I recognition
sequences
Protein expression
P53 PARP-1 p53 and PARP-1
RARa bcr-SV40 minichromosomes *
a ,
b ,
Naked plasmid DNA +
c ++
Cellular chromosomes *, ,
Cellular chromosomes, I-Sce I cleavage ++ +
aSignificant increase of recombination frequency.
bNo significant change of recombination frequency.
cSignificant decrease of recombination frequency.
1046 Nucleic Acids Research, 2006, Vol. 34, No. 3on S-phase progression under the conditions of the SV40-
and EGFP-based recombination measurements, respectively,
which altogether argues against a critical role of replicational
stress in the antagonistic effect of PARP-1 described here.
PARP-1 has also been shown to play a fundamental role
in chromatin condensation and decondensation, particularly
through trans-poly(ADP-ribosyl)ation of histones and high-
mobility group proteins (1,3). Additionally, binding of
PARP-1 to DNA is enhanced speciﬁcally by histones (74).
Therefore, PARP-1 could act on the topoisomerase I pathway
via chromatin remodelling activities. However, under condi-
tions of p53-mediated recombination enhancement, but
without exogenously expressed p53, PARP-1 did not exert
signiﬁcant recombination regulatory activities. This phe-
nomenon suggests that PARP-1 does not have a direct
regulatory inﬂuence on topoisomerase I-dependent recom-
bination events in general. Rather PARP-1 appears to revert
the effect of p53 on topoisomerase I speciﬁcally. These results
may be surprising because PARP-1 downregulates DSB repair
independently of p53 [(28), this study]. In conclusion, a bio-
chemical activity of PARP-1 that is different from its catalytic
activity must be responsible for the modulation of p53/
topoisomerase I activities leading to increased recombination.
Major clues to the mechanism underlying the antagonistic
role of PARP-1 in p53/topoisomerase I-promoted recombina-
tion may come from the results obtained with PARP-DBD.
PARP-DBD represents a dominant negative PARP-1 mutant
with respect to poly(ADP-ribosyl)ation (51,52). Ferro and
Olivera (75) reported that covalent poly(ADP-ribosyl)ation
inhibits topoisomerase I. On the other hand, Malanga and
Althaus (76) saw that poly(ADP-ribose) formation enhances
topoisomerase I-mediated break resealing. Consistent with the
latter report, it was shown that recruitment of XRCC1 and
DNA ligase III by PARP-1 as well as rejoining of DSBs via
the novel PARP-1/XRCC1/DNA ligase III-dependent route
relies on poly(ADP-ribose) synthesis (5,6,19,77). Given that
poly(ADP-ribosyl)ation is suppressed in PARP-DBD but not
PARP-1 expressing cells, these mechanisms cannot explain
the anti-recombinogeniceffect described inthisstudy,because
we did not obtain signiﬁcantly different results with PARP-1
and PARP-DBD in EGFP-based measurements of spontan-
eous HR on cellular chromosomes. However, mapping studies
of the PARP-1 domain interacting with topoisomerase I
showed that PARP-DBD is sufﬁcient for topoisomerase I
binding (45). Interestingly, p53 contacts the core of
topoisomerase I (amino acids 140–484), i.e. a region overlap-
ping with the PARP-1 interactions sites from amino acid 209–
400 and 626–765 (45,78,79). Therefore, it is conceivable that
PARP-1 competes with p53 for binding to topoisomerase I
or even destabilizes p53/topoisomerase I-DNA complexes
(Figure 6).
Covalent topoisomerase I–DNA complexes are normally
transient but can be stabilized by the chemotherapeutic
agent camptothecin (80) and by various DNA lesions (81).
p53 increases dissociation of topoisomerase I covalently
bound to DNA, which represents the limiting step during
topoisomerase I-mediated repair, particularly, when it is
trapped on damaged DNA (48). According to a recent report
(82), p53 may also trigger proteasomal degradation of topoi-
somerase I covalently bound to DNA and thereby accelerate
complete removal. In contrast, PARP-1 (via the PARP-DBD)
appears to increase the binding afﬁnity of topoisomerase I
to substrate DNA and to stimulate the formation of cova-
lent topoisomerase I–DNA complexes (45,79). Therefore,
although both factors cause a net increase in topoisomerase
I activity (45,46,49), opposing effects of p53 and PARP-1
on topoisomerase I–DNA complex dynamics could be
the molecular basis for the direct antagonizing activity in
recombination.
Wild-type p53 was demonstrated to recruit topoisomerase I
to the genomic DNA in response to DNA damage (41,83,84).
Using live cell imaging Yung et al. (49) demonstrated that
PARP-1 and topoisomerase I colocalize throughout the cell
cycle, butin response to DNA damage PARP-1-topoisomerase
I interactions are disrupted due to PARP-1 auto-modiﬁcation.
Therefore, topoisomerase I may be connected to different
cellular processes by speciﬁc complex partners that contact
topoisomerase I in a mutually exclusive manner. According
to this model, p53 may represent the molecular link to recom-
binative repair of speciﬁc DNA lesions such as complex
DSBs which are generated by ionizing irradiation and repa-
ired slowly. PARP-1 may block this activity in undamaged,
cycling cells and rather link topoisomerase I to transcription
and DNA replication. Any shift of the delicate balance
between the different topoisomerase I functions will have
major implications for cellular genome stability, because
trapped topoisomerase I–DNA complexes initiate illegitimate
recombination events with topoisomerase I molecules bound
elsewhere in the genome (41,84,85).
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